Arcadia Biosciences (RKDA) Expected to Announce Earnings on Wednesday

Arcadia Biosciences (NASDAQ:RKDA) is projected to post its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect Arcadia Biosciences to post earnings of ($0.66) per share and revenue of $1.40 million for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, April 2, 2026 at 4:00 PM ET.

Arcadia Biosciences Price Performance

Arcadia Biosciences stock opened at $1.70 on Wednesday. Arcadia Biosciences has a 1 year low of $1.53 and a 1 year high of $6.71. The firm’s 50 day moving average price is $1.94 and its 200-day moving average price is $2.96. The stock has a market cap of $2.94 million, a P/E ratio of 0.67 and a beta of 0.57.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Arcadia Biosciences in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has a consensus rating of “Sell”.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, founded in 2002 and headquartered in Davis, California, is an agricultural biotechnology company dedicated to developing crops and food ingredients that promote health and sustainability. By harnessing advanced genomics and precision‐breeding technologies, Arcadia creates proprietary trait platforms designed to enhance crop performance, nutritional value, and resilience to environmental stressors. The company’s scientific expertise focuses on non-transgenic approaches, enabling the delivery of novel traits without introducing foreign DNA.

Arcadia’s operations span two main segments: Crop Traits and Food Ingredients.